{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:33:49Z","timestamp":1787787229488,"version":"build-2784847793"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital of Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104976","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:26:59Z","timestamp":1759541219000},"page":"104976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Immune checkpoint inhibitor-related thrombocytopenia: Current status and future perspectives"],"prefix":"10.1016","volume":"216","author":[{"given":"Peng-Fei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Cui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Qiong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Xuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2025.104976_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17387","article-title":"Immune thrombocytopenia after immune checkpoint inhibitor therapy","volume":"193","author":"Amanam","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1186\/s12885-023-11558-y","article-title":"The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma","volume":"23","author":"Aslan","year":"2023","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104976_bib3","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2020-0021","article-title":"Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy","volume":"6","author":"Assi","year":"2020","journal-title":"Future Sci. OA"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104976_bib4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1538-7836.2009.03360.x","article-title":"Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management","volume":"7","author":"Aster","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104976_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"Hemasphere"},{"issue":"16, 2021","key":"10.1016\/j.critrevonc.2025.104976_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.critrevonc.2025.104976_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.890166","article-title":"Development of immunotherapy strategies targeting tumor microenvironment is fiercely ongoing","volume":"13","author":"Bai","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104976_bib8","first-page":"187","article-title":"Platelet destruction in immune thrombocytopenia. Understanding the mechanisms","volume":"36","author":"Bakchoul","year":"2015","journal-title":"Hamostaseologie"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104976_bib9","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol. Dial. Transpl."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104976_bib11","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104976_bib12","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdx159","article-title":"Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin\u2019s lymphoma","volume":"28","author":"Bulbul","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104976_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fphar.2019.00454","article-title":"Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia","volume":"10","author":"Calvo","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Cardona","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104976_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104976_bib17","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s40472-021-00321-6","article-title":"Immunosuppression considerations for older kidney transplant recipients","volume":"8","author":"Cheungpasitporn","year":"2021","journal-title":"Curr. Transplant. Rep."},{"issue":"10460","key":"10.1016\/j.critrevonc.2025.104976_bib19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"issue":"10460","key":"10.1016\/j.critrevonc.2025.104976_bib20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104976_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib22","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104976_bib23","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1078155219887212","article-title":"Pembrolizumab-induced thrombotic thrombocytopenic purpura","volume":"26","author":"Dickey","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104976_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4227","article-title":"Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use","volume":"9","author":"Dougherty","year":"2021","journal-title":"Clin. Case Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104976_bib25","article-title":"Immune checkpoint Inhibitor-Associated thrombotic thrombocytopenic purpura in a patient with metastatic Non-Small-Cell lung cancer","volume":"13","author":"De Filippis","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2025.104976_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","article-title":"Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review","author":"Ghanem","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib27","article-title":"Immune-mediated colitis after immune checkpoint inhibitor therapy","author":"Giesler","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104976_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100686","article-title":"A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab","volume":"45","author":"Goda","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104976_bib29","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Committee EG. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib30","first-page":"1","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","author":"Haddad","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104976_bib31","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"3.4","key":"10.1016\/j.critrevonc.2025.104976_bib32","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2152\/jmi.70.516","article-title":"A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:case report","volume":"70","author":"Harada","year":"2023","journal-title":"J. Med. Investig."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13256-019-2245-y","article-title":"Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature","volume":"13","author":"Hasegawa","year":"2019","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.critrevonc.2025.104976_bib34","article-title":"Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma","volume":"32","author":"Hata","year":"2020","journal-title":"Urol. Case Rep."},{"key":"10.1016\/j.critrevonc.2025.104976_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/bs.mcb.2024.07.006","article-title":"In vitro screening methods of novel immune checkpoint inhibitors related to t cell infiltration and anti-PD-1 resistance","volume":"190","author":"He","year":"2024","journal-title":"Methods Cell Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104976_bib36","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104976_bib37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3324\/haematol.2014.115634","article-title":"Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro","volume":"100","author":"Iraqi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104976_bib38","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00277-020-04053-y","article-title":"Acquired amegakaryocytic thrombocytopenic purpura possibly induced by anti-PD-1 antibody","volume":"99","author":"Iyama","year":"2020","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/imt-2017-0100","article-title":"Immune-Mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab","volume":"10","author":"Jotatsu","year":"2018","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104976_bib40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/annonc\/mdv580","article-title":"Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on b cells","volume":"27","author":"Kanameishi","year":"2016","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104976_bib41","doi-asserted-by":"crossref","DOI":"10.1159\/000477968","article-title":"K\ufe85\u0661l\ufe85\u0661ckap S. Immune thrombocytopenia induced by nivolumab in a metastatic Non-Small cell lung cancer patient","volume":"40","author":"Karakas","year":"2017","journal-title":"Oncol. Res. Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","article-title":"Thyroid disorders induced by immune checkpoint inhibitors","volume":"85","author":"Karaviti","year":"2024","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104976_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjh.15085","article-title":"PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia","volume":"180","author":"Kasamatsu","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104976_bib44","first-page":"2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib45","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4081\/cp.2020.1249","article-title":"Severe immune thrombocytopenia induced by a single dose of nivolumab in a patient with advanced Non-Small cell lung cancer","volume":"10","author":"Khorasanchi","year":"2020","journal-title":"Clin. Pract."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12951-023-02083-y","article-title":"Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy","volume":"21","author":"Kiaie","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"03","key":"10.1016\/j.critrevonc.2025.104976_bib47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0039-1683416","article-title":"Epidemiology and clinical manifestations of immune thrombocytopenia","volume":"39","author":"Kohli","year":"2019","journal-title":"Hamostaseologie"},{"issue":"03","key":"10.1016\/j.critrevonc.2025.104976_bib48","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0039-1683416","article-title":"Epidemiology and clinical manifestations of immune thrombocytopenia","volume":"39","author":"Kohli","year":"2019","journal-title":"Hamostaseologie"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104976_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/jjco\/hyu222","article-title":"Treatment possibilities of ipilimumab-induced thrombocytopenia\u2014case study and literature review","volume":"45","author":"Kopeck\u00fd","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104976_bib51","first-page":"3594","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104976_bib53","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","article-title":"64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104976_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101298","article-title":"CTLA-4 (CD152): a versatile receptor for immune-based therapy","volume":"42","author":"Lingel","year":"2019","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib55","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104976_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.530478","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitors in solid cancer: case report and literature review","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib57","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fonc.2020.530478","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitors in solid cancer: case report and literature review","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib58","first-page":"2024","article-title":"Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104976_bib59","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.3390\/jcm13216477","article-title":"Implementation of primary immune thrombocytopenia clinical practice guidelines for management of pregnancy","volume":"13","author":"Llaneza","year":"2024","journal-title":"J. Clin. Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104976_bib60","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/1759-7714.14106","article-title":"Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: a case report","volume":"12","author":"Makiguchi","year":"2021","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104976_bib61","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.104976_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: a pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib64","article-title":"Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer","volume":"28","author":"Mori","year":"2019","journal-title":"Respir. Med. Case Rep."},{"key":"10.1016\/j.critrevonc.2025.104976_bib65","article-title":"Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer","volume":"28","author":"Mori","year":"2019","journal-title":"Respir. Med. Case Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib66","doi-asserted-by":"crossref","first-page":"877","DOI":"10.21873\/invivo.11852","article-title":"Severe thrombocytopenia associated with pembrolizumab in patients with non-small cell lung cancer (NSCLC): a case report and literature review","volume":"34","author":"Mouri","year":"2020","journal-title":"Vivo"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib67","doi-asserted-by":"crossref","first-page":"877","DOI":"10.21873\/invivo.11852","article-title":"Severe thrombocytopenia associated with pembrolizumab in patients with Non-small cell lung cancer (NSCLC): a case report and literature review","volume":"34","author":"Mouri","year":"2020","journal-title":"Vivo"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104976_bib68","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib69","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104976_bib70","first-page":"3616","article-title":"Clinical significance of HLA-DRB1* 0410 in Japanese patients with idiopathic thrombocytopenic purpura","volume":"91","author":"Nomura","year":"1998","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"10397","key":"10.1016\/j.critrevonc.2025.104976_bib71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"issue":"10397","key":"10.1016\/j.critrevonc.2025.104976_bib72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12885-023-10649-0","article-title":"Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"23","author":"Pang","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102345","article-title":"Immune attack on megakaryocytes in immune thrombocytopenia","volume":"8","author":"Petito","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104976_bib75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000479237","article-title":"A case of immune thrombocytopenia as a rare side effect of an immunotherapy with PD1-Blocking agents for metastatic melanoma","volume":"44","author":"Pf\u00f6hler","year":"2017","journal-title":"Transfus. Med. Hemother"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib76","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1574886317666220324100356","article-title":"Potential drug-drug interactions between anti-cancer drugs and other medications in lung cancer patients: a retrospective study","volume":"18","author":"Pinto","year":"2023","journal-title":"Curr. Drug Saf."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104976_bib77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/cancers10110441","article-title":"Impacts of cancer on platelet production, activation and education and mechanisms of Cancer-Associated thrombosis","volume":"10","author":"Plantureux","year":"2018","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104976_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104976_bib80","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.21037\/tlcr-22-745","article-title":"Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report","volume":"11","author":"Qiu","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104976_bib81","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non\ufed7\u00b0\u00b1small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib82","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fonc.2024.1353896","article-title":"Immune checkpoint inhibitor-related acquired amegakaryocytosis thrombocytopenia: a case report and literature review","volume":"14","author":"Rivet","year":"2024","journal-title":"Front. Oncol."},{"issue":"44","key":"10.1016\/j.critrevonc.2025.104976_bib83","doi-asserted-by":"crossref","first-page":"27460","DOI":"10.18632\/oncotarget.25446","article-title":"PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy","volume":"9","author":"Rolfes","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104976_bib84","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2015.10.073","article-title":"Two cases of immune thrombocytopenia associated with pembrolizumab","volume":"54","author":"Le Roy","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib85","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/annonc\/mdx693","article-title":"A fatal allo-and immune-mediated thrombocytopenia with a PD-L1 inhibitor","volume":"29","author":"Leroy","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104976_bib86","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/annonc\/mdx693","article-title":"A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor","volume":"29","author":"Leroy","year":"2018","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104976_bib87","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14712598.2022.2038132","article-title":"Immune checkpoint inhibitors for the treatment of melanoma","volume":"22","author":"Sabbatino","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104976_bib88","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/med.21765","article-title":"Understanding the tumor microenvironment for effective immunotherapy","volume":"41","author":"Sadeghi Rad","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104976_bib89","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41577-023-00834-4","article-title":"The role of platelets in immune-mediated inflammatory diseases","volume":"23","author":"Scherlinger","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104976_bib90","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104976_bib93","article-title":"A case of anti-synthetase syndrome successfully treated with mycophenolate mofetil and rituximab but no corticosteroids","volume":"9","author":"Sieradzka","year":"2022","journal-title":"Eur. J. Case Rep. Intern. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104976_bib94","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/cancers17091422","article-title":"Clinical applications of the molecular landscape of melanoma: integration of research into diagnostic and therapeutic strategies","volume":"17","author":"Szab\u00f3","year":"2025","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104976_bib95","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2169\/internalmedicine.7581-21","article-title":"Pembrolizumab-related immune thrombocytopenia in a patient with lung adenocarcinoma treated by radiotherapy: potential Immune-related adverse event elicited by radiation therapy","volume":"61","author":"Tamanoi","year":"2022","journal-title":"Intern. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104976_bib96","doi-asserted-by":"crossref","first-page":"342","DOI":"10.31083\/j.fbl2910342","article-title":"Immune thrombocytopenia: immune dysregulation and genetic perturbations deciphering the fate of platelets","volume":"29","author":"Tariq","year":"2024","journal-title":"Front. Biosci. Landmark"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104976_bib97","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines","volume":"18","author":"Thompson","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2025.104976_bib98","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2018.02.018","article-title":"Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma","volume":"119","author":"Tokumo","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2025.104976_bib99","first-page":"1","article-title":"Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management","author":"Triantafyllou","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104976_bib100","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2013.087874","article-title":"Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein Ib\ufea7\u0661 and fc RIIa in immune thrombocytopenia","volume":"98","author":"Urbanus","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104976_bib101","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key Immune-Related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104976_bib102","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ejh.13705","article-title":"T cell-mediated autoimmunity in immune thrombocytopenia","volume":"108","author":"Vrbensky","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104976_bib103","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.thromres.2018.04.007","article-title":"Platelet activation and antiplatelet therapy in sepsis: a narrative review","volume":"166","author":"Wang","year":"2018","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104976_bib104","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/21645515.2017.1342913","article-title":"Percentages of PD-1+ CD4+ t cells and PD-L1+ DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia","volume":"14","author":"Wang","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104976_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.615941","article-title":"Immune checkpoint-related gene polymorphisms are associated with primary immune thrombocytopenia","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"issue":"43","key":"10.1016\/j.critrevonc.2025.104976_bib106","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017608","article-title":"PD-1\/PD-L1 pathway activation restores the imbalance of Th1\/Th2 and treg\/Th17 cells subtypes in immune thrombocytopenic purpura patients","volume":"98","author":"Wu","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.critrevonc.2025.104976_bib107","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2021.790051","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitrs in lung cancer: case report and literature review","volume":"12","author":"Xie","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104976_bib108","doi-asserted-by":"crossref","first-page":"5881886","DOI":"10.21037\/apm-21-794","article-title":"Delayed thrombocytopenia as a rare but serious adverse event secondary to immune checkpoint inhibitor: a case report","volume":"10","author":"Zhou","year":"2021","journal-title":"Ann. Palliat. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104976_bib109","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.21037\/apm-21-794","article-title":"Delayed thrombocytopenia as a rare but serious adverse event secondary to immune checkpoint inhibitor: a case report","volume":"10","author":"Zhou","year":"2021","journal-title":"Ann. Palliat. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:13:14Z","timestamp":1767388394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":109,"alternative-id":["S1040842825003646"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104976","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-related thrombocytopenia: Current status and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104976"}}